Zevra Therapeutics, Inc. (ZVRA) stock
Close on Nov 16, 2026Market cap $549.30MP/E 9.9Yield –
Zevra Therapeutics, Inc. grew revenue 119.4% to $136.07M over the twelve months to Jun 30, 2026. Free cash flow was $32.62M. At the latest close the market valued the company at $549.30M, 9.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $549.30M
- P/E ratio
- 9.9
- Price to sales
- 4.04
- Price to book
- 2.52
- Dividend yield
- –
- Free cash flow yield
- 5.94%
Fundamentals
- Revenue
- $136.07M
- Net income
- $58.26M
- EPS, diluted
- $0.93
- Free cash flow
- $32.62M
- Book value per share
- $3.55
- Diluted shares
- 61M
Trading
- Next earnings
- Mar 8, 2027 (estimated, after the close)
- Previous close
- $9.08
- Open
- $9.11
- Day's range
- $8.92 – $9.79
- Volume
- 1,761,713
- Average volume (20 days)
- 1,110,889
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- 52-week range
- $8.01 – $15.04
- RSI (14 days)
- 38.4
- Volatility (1 year)
- 63.6%
- Relative volume
- 1.65×
On 2 of our idea lists: Undervalued and financially sound, Small-cap growth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZVRA | S&P 500 | Difference | ZVRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.9% | -3.1% | −3.9 pts | ||
| 3 months | -18.3% | -4.5% | −13.8 pts | ||
| Year to date | +3.2% | +9.4% | −6.1 pts | ||
| 1 year | +4.2% | +11.3% | −7.1 pts | ||
| 3 years | +116.1% | +70.4% | +45.7 pts | +29.3% | +19.4% |
| 5 years | +3.5% | +68.6% | −65.1 pts | +0.7% | +11.0% |
| 10 years | -85.9% | +297.7% | −383.6 pts | -17.8% | +14.8% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zevra Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
About Zevra Therapeutics
Pharmaceutical Preparations
Zevra Therapeutics, Inc. is a pharmaceutical company that develops and commercializes therapies for rare diseases. Its commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for attention deficit hyperactivity disorder, marketed through partners. The company also advances clinical candidates such as celiprolol for vascular Ehlers-Danlos syndrome and KP1077 for sleep disorders. Its products serve adult and pediatric patients with rare neurodegenerative, metabolic, and genetic conditions.
Company profile, executives and historyZevra Therapeutics stock: common questions
What is Zevra Therapeutics's stock price?
ZVRA closed at $9.25 on Nov 16, 2026, up 1.87% on the day. Over the past 52 weeks it traded between $8.01 and $15.04.
What is Zevra Therapeutics's market cap?
Zevra Therapeutics was worth $549.30M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is ZVRA's P/E ratio?
ZVRA trades at 9.9 times earnings, based on diluted earnings per share of $0.93 over the twelve months to Jun 30, 2026.
How much revenue does Zevra Therapeutics make?
Zevra Therapeutics reported revenue of $136.07M for the twelve months to Jun 30, 2026, up 119.4% from a year earlier.
Does Zevra Therapeutics pay a dividend?
No. Zevra Therapeutics has not paid a cash dividend over the last twelve months.
When does Zevra Therapeutics report earnings next?
Zevra Therapeutics is expected to report Q4 FY2026 results on Mar 8, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ZVRA stock performed over the past year?
Including dividends, ZVRA returned +4.2% over the past year, against +11.3% for the S&P 500.
How many ZVRA shares are sold short?
7M shares were sold short at the latest FINRA report, 11.18% of the float, or 9.5 days of average trading volume.
Who are Zevra Therapeutics's competitors?
Companies most similar to Zevra Therapeutics by business, industry and size include ETON, AGIO, SPRY, GYRE, AMLX.
See a number that looks wrong?